Literature DB >> 7625882

Effects of chronic caffeine on adenosine, dopamine and acetylcholine systems in mice.

D Shi1, O Nikodijević, K A Jacobson, J W Daly.   

Abstract

Chronic ingestion of caffeine by male NIH Swiss strain mice leads in about 3 days to a significant increase in A1-adenosine, nicotinic and muscarinic receptors, and a significant decrease of beta 1-adrenoceptors in cerebral cortical membranes. Plasma levels of caffeine in the chronically treated mice range from 0.70 to 5.7 micrograms/ml. The changes in receptors reverse after withdrawal of caffeine within 7 days. An increase in nitrendipine binding sites, associated with L-type calcium channels, also occurs within 4 days and has reversed in 7 days after withdrawal. There is no change in the levels of striatal nicotinic receptors of D2-dopamine receptors, nor of [3H]cocaine binding to dopamine uptake sites. Levels of opioid receptors are either increased (delta) or unaltered (mu, kappa). sigma-Receptors are unaltered. Stimulations of striatal adenylate cyclase by forskolin, dopamine and NECA are not significantly affected after chronic caffeine ingestion. The adenosine agonist, NECA, reverses the amphetamine-elicited increases in locomotor activity and partly reverses the cocaine-elicited increases. The NECA dose-response curve is multiphasic (depression, stimulation and then depression) versus amphetamine in control mice, but only depressant versus amphetamine in chronic caffeine mice, while being multiphasic versus cocaine in both control and chronic caffeine mice. NECA reverses the stimulation of locomotor activity elicited by the muscarinic antagonist, scopolamine, and is more effective in the chronic caffeine mice. The behavioral depressant effects of the muscarinic agonist, oxotremorine, are not markedly altered after chronic caffeine ingestion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7625882      PMCID: PMC3432916     

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  26 in total

1.  A highly sensitive adenylate cyclase assay.

Authors:  Y Salomon; C Londos; M Rodbell
Journal:  Anal Biochem       Date:  1974-04       Impact factor: 3.365

2.  Downregulation of nicotinic receptor function after chronic nicotine infusion.

Authors:  M J Marks; S R Grady; A C Collins
Journal:  J Pharmacol Exp Ther       Date:  1993-09       Impact factor: 4.030

3.  Chronic effects of ethanol on central adenosine function of mice.

Authors:  J W Daly; D Shi; V Wong; O Nikodijevic
Journal:  Brain Res       Date:  1994-07-04       Impact factor: 3.252

4.  Up-regulation of brain [3H]diazepam binding sites in chronic caffeine-treated rats.

Authors:  P H Wu; V L Coffin
Journal:  Brain Res       Date:  1984-02-27       Impact factor: 3.252

5.  Adenosine receptors in brain membranes: binding of N6-cyclohexyl[3H]adenosine and 1,3-diethyl-8-[3H]phenylxanthine.

Authors:  R F Bruns; J W Daly; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

6.  Caffeine down-regulates beta adrenoreceptors in rat forebrain.

Authors:  M R Goldberg; P W Curatolo; C S Tung; D Robertson
Journal:  Neurosci Lett       Date:  1982-07-20       Impact factor: 3.046

7.  Interactions in the behavioral effects of methylxanthines and adenosine derivatives.

Authors:  J J Katims; Z Annau; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1983-10       Impact factor: 4.030

8.  Chronic caffeine alters the density of adenosine, adrenergic, cholinergic, GABA, and serotonin receptors and calcium channels in mouse brain.

Authors:  D Shi; O Nikodijević; K A Jacobson; J W Daly
Journal:  Cell Mol Neurobiol       Date:  1993-06       Impact factor: 5.046

9.  Adenosine receptors and behavioral actions of methylxanthines.

Authors:  S H Snyder; J J Katims; Z Annau; R F Bruns; J W Daly
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

10.  Locomotor activity in mice during chronic treatment with caffeine and withdrawal.

Authors:  O Nikodijević; K A Jacobson; J W Daly
Journal:  Pharmacol Biochem Behav       Date:  1993-01       Impact factor: 3.533

View more
  8 in total

1.  Regulation of hippocampal cannabinoid CB1 receptor actions by adenosine A1 receptors and chronic caffeine administration: implications for the effects of Δ9-tetrahydrocannabinol on spatial memory.

Authors:  Vasco C Sousa; Natália Assaife-Lopes; Joaquim A Ribeiro; Judith A Pratt; Ros R Brett; Ana M Sebastião
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

2.  Chronic effects of xanthines on levels of central receptors in mice.

Authors:  D Shi; J W Daly
Journal:  Cell Mol Neurobiol       Date:  1999-12       Impact factor: 5.046

Review 3.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

4.  The role of adenosine receptors in the central action of caffeine.

Authors:  John W Daly; Dan Shi; Olga Nikodijevic; Kenneth A Jacobson
Journal:  Pharmacopsychoecologia       Date:  1994

Review 5.  Adenosine receptor ligands: differences with acute versus chronic treatment.

Authors:  K A Jacobson; D K von Lubitz; J W Daly; B B Fredholm
Journal:  Trends Pharmacol Sci       Date:  1996-03       Impact factor: 14.819

6.  Caffeinated Alcoholic Beverages - An Emerging Trend in Alcohol Abuse.

Authors:  Kelle M Franklin; Sheketha R Hauser; Richard L Bell; Eric A Engleman
Journal:  J Addict Res Ther       Date:  2013-08-20

7.  Regulation of cerebrospinal fluid production by caffeine consumption.

Authors:  Myoung-Eun Han; Hak-Jin Kim; Young-Suk Lee; Dong-Hyun Kim; Joo-Taek Choi; Chul-Sik Pan; Sik Yoon; Sun-Yong Baek; Bong-Seon Kim; Jae-Bong Kim; Sae-Ock Oh
Journal:  BMC Neurosci       Date:  2009-09-03       Impact factor: 3.288

8.  Orchestration of Dopamine Neuron Population Activity in the Ventral Tegmental Area by Caffeine: Comparison With Amphetamine.

Authors:  Ornella Valenti; Alice Zambon; Stefan Boehm
Journal:  Int J Neuropsychopharmacol       Date:  2021-10-23       Impact factor: 5.176

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.